Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MAP2K1 P124S

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	PLX4720 Resistant: D – Preclinical PLX4720 Resistant : D	PLX4720 Resistant: D – Preclinical PLX4720 Resistant : D